SubsidieMeestersTransforming bone cancer therapy with composite biomaterials encapsulating plasma-generated RONS
TRANSFORMER aims to develop a novel therapy combining cold atmospheric plasma-treated hydrogels with biomaterials for simultaneous osteosarcoma treatment and bone regeneration, enhancing patient outcomes.
Projectdetails
Introduction
Improving the survival of patients with osteosarcoma has long proved challenging. Osteosarcoma is a rare bone cancer (less than 0.2% of all cancers). However, it affects mainly children and young adolescents.
Standard Therapy
The standard therapy for osteosarcoma consists of the surgeon removing the entire tumor with negative margins (resection of larger areas of bone than the tumor itself) to ensure that no cancer cells are found at the edge of the tissue removed.
This means that in some cases, these surgeries associate limb amputation, and even when it is not the case, most patients that undergo limb-sparing surgery need reconstructive surgery to regain limb function.
Project Aim
The aim of TRANSFORMER is to bring closer to the market a solution that will allow simultaneous treatment of bone cancer in the absence of side effects while allowing bone regeneration.
The product to be developed in TRANSFORMER combines, for the first time, bone regeneration biomaterials with an innovative therapy for cancer that, in contrast to chemotherapy, has shown no secondary effects: cold atmospheric plasma-treated hydrogels. The technology is protected by two PCT.
Value Proposition
TRANSFORMER's value proposition is that the product focused on in TRANSFORMER will have a double advantage for patients and clinicians: it will be a local therapy that will allow simultaneous bone cancer treatment and bone regeneration.
Objectives
TRANSFORMER is structured along several objectives:
- To preclinically validate the plasma-treated biocomposite as a potential therapy against bone cancer and towards bone regeneration, advancing the technology from TRL of 3 to 5, subsequently making it ready for clinical development and transfer to a spin-off or a third-party company.
- To consolidate our IP position.
- To adapt the development roadmap to the regulatory requirements.
- To build a comprehensive business case for the exploitation of the technology and subsequent strategy for knowledge transfer.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-11-2022 |
| Einddatum | 30-4-2024 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- UNIVERSITAT POLITECNICA DE CATALUNYApenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
BioBone: Bioactive Hydrogel-based Implants to Induce Bone RegenerationThe project aims to enhance bone regeneration after tumor resection by developing 3D-printed porous titanium implants integrated with bioactive materials, improving patient outcomes and reducing complications. | ERC Proof of... | € 150.000 | 2024 | Details |
Targeting the undruggable: Leveraging neomorphic DNA-binding preferences of chimeric fusion oncogenes to promote cancer suicideThis project aims to develop a novel viral vector strategy that leverages oncogenic transcription factors to selectively induce cancer cell suicide in aggressive tumors like Ewing sarcoma. | ERC Consolid... | € 1.992.235 | 2024 | Details |
Development of a lung METAstasis-on-a-CHIP model for osteosarcoma as a biomimetic testing platform for drug discovery and therapeutic innovationMETA-CHIP aims to develop a lung metastasis-on-a-chip model for osteosarcoma to enhance drug development and predict patient responses to therapies in real-time. | ERC Starting... | € 1.499.884 | 2024 | Details |
Development of patient “Ossicle” for the personalized modelling of bone-developing cancers and therapeutic testingOssiGel aims to standardize the formation of human mini-bones in mice for studying bone-developing cancers and testing personalized therapeutics effectively. | ERC Proof of... | € 150.000 | 2022 | Details |
Regenerative Stenting for Osteoporotic Vertebral Fracture RepairRESTORE aims to revolutionize osteoporotic vertebral fracture treatment by using 3D-printed biodegradable stents and thermoresponsive hydrogels for personalized bone regeneration and repair. | ERC Consolid... | € 2.039.473 | 2024 | Details |
BioBone: Bioactive Hydrogel-based Implants to Induce Bone Regeneration
The project aims to enhance bone regeneration after tumor resection by developing 3D-printed porous titanium implants integrated with bioactive materials, improving patient outcomes and reducing complications.
Targeting the undruggable: Leveraging neomorphic DNA-binding preferences of chimeric fusion oncogenes to promote cancer suicide
This project aims to develop a novel viral vector strategy that leverages oncogenic transcription factors to selectively induce cancer cell suicide in aggressive tumors like Ewing sarcoma.
Development of a lung METAstasis-on-a-CHIP model for osteosarcoma as a biomimetic testing platform for drug discovery and therapeutic innovation
META-CHIP aims to develop a lung metastasis-on-a-chip model for osteosarcoma to enhance drug development and predict patient responses to therapies in real-time.
Development of patient “Ossicle” for the personalized modelling of bone-developing cancers and therapeutic testing
OssiGel aims to standardize the formation of human mini-bones in mice for studying bone-developing cancers and testing personalized therapeutics effectively.
Regenerative Stenting for Osteoporotic Vertebral Fracture Repair
RESTORE aims to revolutionize osteoporotic vertebral fracture treatment by using 3D-printed biodegradable stents and thermoresponsive hydrogels for personalized bone regeneration and repair.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Live Cell Spectroscopy Analysis for Personalised Particle Radiation Therapy of Metastatic Bone CancerBoneOscopy aims to revolutionize metastatic bone cancer treatment by enabling daily monitoring during particle radiotherapy, enhancing personalized care and treatment efficacy. | EIC Pathfinder | € 3.069.321 | 2025 | Details |
A minimally Invasive surgical platform aGainst paNcreatIc and biliary Tract cancErs using cold atmospheric PLASMAThis project aims to develop a novel cold atmospheric pressure plasma system for minimally invasive treatment of pancreatic and biliary tract cancers, integrating advanced modeling and in-vivo testing. | EIC Pathfinder | € 2.792.500 | 2024 | Details |
Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineeringThe project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer. | EIC Accelerator | € 2.434.790 | 2025 | Details |
Drug solution for bone fracture nonunionsGenera Research aims to develop OSTEOGROW-C, a novel biological drug using patients' blood to treat bone fracture nonunion, promising effective regeneration and reduced complications. | EIC Accelerator | € 2.499.999 | 2025 | Details |
2D Material-Based Multiple Oncotherapy Against Metastatic Disease Using a Radically New Computed Tomography ApproachPERSEUS aims to develop a novel nanotechnology-based cancer therapy that activates under CT imaging to treat deep-seated, drug-resistant tumors with minimal side effects. | EIC Pathfinder | € 2.740.675 | 2023 | Details |
Live Cell Spectroscopy Analysis for Personalised Particle Radiation Therapy of Metastatic Bone Cancer
BoneOscopy aims to revolutionize metastatic bone cancer treatment by enabling daily monitoring during particle radiotherapy, enhancing personalized care and treatment efficacy.
A minimally Invasive surgical platform aGainst paNcreatIc and biliary Tract cancErs using cold atmospheric PLASMA
This project aims to develop a novel cold atmospheric pressure plasma system for minimally invasive treatment of pancreatic and biliary tract cancers, integrating advanced modeling and in-vivo testing.
Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineering
The project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer.
Drug solution for bone fracture nonunions
Genera Research aims to develop OSTEOGROW-C, a novel biological drug using patients' blood to treat bone fracture nonunion, promising effective regeneration and reduced complications.
2D Material-Based Multiple Oncotherapy Against Metastatic Disease Using a Radically New Computed Tomography Approach
PERSEUS aims to develop a novel nanotechnology-based cancer therapy that activates under CT imaging to treat deep-seated, drug-resistant tumors with minimal side effects.